We are live on ! Find out more
ACHN

Achillion Pharmaceuticals
ACHN

Delisted

ACHN was delisted on the 27th of January, 2020.

Back to rankings

121 hedge funds and large institutions have $164M invested in Achillion Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 40 increasing their positions, 40 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

584% more call options, than puts

Call options by funds: $1.17M | Put options by funds: $171K

0% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 40

12% less funds holding

Funds holding: 137 → 121 (-16)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

58% less capital invested

Capital invested by funds: $394M → $164M (-$230M)

59% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 27

Holders
121
Holders Change
-16
Holders Change %
-11.68%
% of All Funds
2.7%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
11
Increased
40
Reduced
40
Closed
27
Calls
$1.17M
Puts
$171K
Net Calls
+$998K
Net Calls Change
+$625K

Top Buyers

Rank Fund Capital Flow
1
MCO
MAK Capital One
New York
+$9.17M
2
AC
Armistice Capital
New York
+$6.5M
3
UBS Group
UBS Group
Switzerland
+$3.71M
4
Citadel Advisors
Citadel Advisors
Florida
+$3.71M
5
Two Sigma Investments
Two Sigma Investments
New York
+$3.17M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$16.5M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$8.75M
3
NC
Nexthera Capital
New York
-$5.83M
4
EC
EcoR1 Capital
California
-$5.76M
5
BB
BB Biotech
Switzerland
-$4.71M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$1.17M -$53.1K -18,778 -2%
CS
27
Candriam SCA
Luxembourg
$1.15M +$212K +75,000 +12%
SIM
28
Spark Investment Management
New York
$1.03M +$1.64M +579,900 +885%
DCM
29
DAFNA Capital Management
California
$1M -$615K -217,454 -26%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$988K -$26.3K -9,316 -1%
D.E. Shaw & Co
31
D.E. Shaw & Co
New York
$723K +$907K +320,949 +240%
Mirae Asset Global Investments
32
Mirae Asset Global Investments
South Korea
$717K +$1.28M +451,197 New
QI
33
QS Investors
New York
$715K – – –
RPAM
34
Rhenman & Partners Asset Management
Sweden
$640K -$608K -215,000 -35%
Stifel Financial
35
Stifel Financial
Missouri
$638K – – –
Citigroup
36
Citigroup
New York
$584K +$420K +148,666 +68%
AA
37
ALPS Advisors
Colorado
$509K +$212K +75,105 +31%
TCM
38
Tekla Capital Management
Massachusetts
$507K -$413K -145,928 -31%
Two Sigma Advisers
39
Two Sigma Advisers
New York
$489K +$831K +293,815 +2,097%
Morgan Stanley
40
Morgan Stanley
New York
$469K +$151K +53,450 +22%
AIM
41
Assured Investment Management
New York
$456K +$753K +266,490 +1,301%
Jacobs Levy Equity Management
42
Jacobs Levy Equity Management
New Jersey
$426K +$103K +36,500 +16%
Deutsche Bank
43
Deutsche Bank
Germany
$423K -$1.57M -554,932 -68%
TCIM
44
TIAA CREF Investment Management
New York
$408K -$76.8K -27,161 -10%
CS
45
Credit Suisse
Switzerland
$396K +$313K +110,738 +81%
Assenagon Asset Management
46
Assenagon Asset Management
Luxembourg
$373K -$3.25M -1,151,384 -83%
California State Teachers Retirement System (CalSTRS)
47
California State Teachers Retirement System (CalSTRS)
California
$333K – – –
AGM
48
Alpine Global Management
New York
$326K +$580K +205,172 New
GCP
49
GSA Capital Partners
United Kingdom
$324K -$156K -55,200 -21%
AllianceBernstein
50
AllianceBernstein
Tennessee
$315K +$37.3K +13,200 +7%
1
2
3 4 5

ACHN Hedge Fund Activity: Q4 2018 in Review

121 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q4 2018, worth a combined $164M — down 58% from $394M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of ACHN and 11 opened new positions — a net loss of 16 holders — while 40 trimmed existing stakes and 40 added.

The largest buyer was MAK Capital One, adding an estimated $9.17M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $16.5M sold.

  • 121 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q4 2018, down from 137 in Q3 2018.
  • Funds reported $164M of Achillion Pharmaceuticals stock for Q4 2018, down 58% quarter-over-quarter.
  • 11 funds opened new Achillion Pharmaceuticals positions in Q4 2018 and 27 closed out, a net change of -16 holders.
  • The largest Achillion Pharmaceuticals buyer in Q4 2018 was MAK Capital One, an estimated $9.17M added.
  • The largest Achillion Pharmaceuticals seller in Q4 2018 was T. Rowe Price Associates, an estimated $16.5M sold.

Based on aggregated 13F filings for Q4 2018.